Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma.

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic...

Tranilast (N- [3',4'-dimethoxycinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite. Initially, tranilast was identified as an anti-allergic agent, and used in the treatment of inflammatory diseases, such as bronchial asthma, atypical dermatitis, allergic conjunctivitis, keloids and hy …

2015年1月1日 · Tranilast (N- [3′,4′-dimethoxycinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite. Initially, tranilast was identified as an anti-allergic agent, and used in the treatment of inflammatory diseases, such as bronchial asthma, atypical dermatitis, allergic conjunctivitis, keloids and hypertrophic scars.

Here, we show that tranilast (TR), an old anti‐allergic clinical drug, is a direct NLRP3 inhibitor. TR inhibits NLRP3 inflammasome activation in macrophages, but has no effects on AIM2 or NLRC4 inflammasome activation.

2020年2月28日 · Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s.

Tranilast is a non-oncology anti-inflammatory drug that exhibits anticancer potential with low toxicity profile. It modulates TGF-β, inhibits apoptosis, angiogenesis and stemness potential of cancer cells. Combination treatment with Tranilast improves efficacy of chemotherapeutic and immunotherapeutic drugs.

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma.

Tranilast will be compounded as various topical dosage forms and strengths based on the prescriber’s request; the therapeutic dose ranges from 0.5-1%. Additionally, tranilast will be compounded as a 0.5-1% topical cream, gel, and ointment for treatment of pruritus.

Tranilast is a well-known anti-allergy medication that directly interacts with NLRP3 NACHT structural domain, preventing NLRP3 activation and inhibiting NLRP3 inflammasome assembly (Huang et al., 2018). Studies indicate that Tranilast can permeate the BBB, as it suppresses glioma growth in rats following oral treatment (Platten et al., 2001).